These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19474786)

  • 1. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.
    Mahungu TW; Nair D; Smith CJ; Egan D; Youle M; Johnson MA; Khoo SH; Back DJ; Owen A
    Clin Pharmacol Ther; 2009 Aug; 86(2):204-11. PubMed ID: 19474786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
    Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
    Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
    Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
    Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
    Ribaudo HJ; Liu H; Schwab M; Schaeffeler E; Eichelbaum M; Motsinger-Reif AA; Ritchie MD; Zanger UM; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford D; Haas DW
    J Infect Dis; 2010 Sep; 202(5):717-22. PubMed ID: 20662624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
    Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
    PLoS One; 2014; 9(1):e86919. PubMed ID: 24497997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
    Wyen C; Hendra H; Vogel M; Hoffmann C; Knechten H; Brockmeyer NH; Bogner JR; Rockstroh J; Esser S; Jaeger H; Harrer T; Mauss S; van Lunzen J; Skoetz N; Jetter A; Groneuer C; Fätkenheuer G; Khoo SH; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2008 Apr; 61(4):914-8. PubMed ID: 18281305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients.
    Masebe TM; Bessong PO; Nwobegahay J; Ndip RN; Meyer D
    Dis Markers; 2012; 32(1):43-50. PubMed ID: 22297601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Kenu E; Court MH
    AIDS; 2009 Oct; 23(16):2101-6. PubMed ID: 19779319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
    Lindfelt T; O'Brien J; Song JC; Patel R; Winslow DL
    Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
    Viljoen M; Karlsson MO; Meyers TM; Gous H; Dandara C; Rheeders M
    Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
    Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
    Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.
    Lee SS; To KW; Lee MP; Wong NS; Chan DP; Li PC; Cheung SW; Chan RC
    Int J STD AIDS; 2014 Mar; 25(3):193-200. PubMed ID: 23970651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
    Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
    J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
    Chou M; Bertrand J; Segeral O; Verstuyft C; Borand L; Comets E; Le Tiec C; Becquemont L; Ouk V; Mentre F; Taburet AM
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4432-9. PubMed ID: 20696882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
    Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
    Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
    PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.
    Nyakutira C; Röshammar D; Chigutsa E; Chonzi P; Ashton M; Nhachi C; Masimirembwa C
    Eur J Clin Pharmacol; 2008 Apr; 64(4):357-65. PubMed ID: 18057928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.